---
title: "China Medical System Revises Interim Dividend for First Half of 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296184471.md"
description: "China Medical System Holdings (HK:0867) revised its interim dividend for the six months ended June 30, 2026, to RMB 0.1634 (HKD 0.189) per share. The payment is scheduled for September 8, 2026, with a record date of September 1 and ex-dividend date of August 28. This adjustment reflects stable cash generation from pharmaceutical operations and a commitment to shareholder returns. Analysts maintain a 'Buy' rating with a HK$16.80 price target."
datetime: "2026-08-18T04:39:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296184471.md)
  - [en](https://longbridge.com/en/news/296184471.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296184471.md)
generator: "portal-rs"
---

# China Medical System Revises Interim Dividend for First Half of 2026

An update from China Medical System Holdings ( (HK:0867) ) is now available.

China Medical System Holdings Limited has revised its interim dividend for the six months ended 30 June 2026, declaring a cash payout of RMB 0.1634 per share, equivalent to HKD 0.189 per share. The adjustment underscores the company’s continued commitment to shareholder returns and reflects stable cash generation from its pharmaceutical operations.

The interim dividend will be paid in Hong Kong dollars, with the record date set for 1 September 2026 and payment scheduled on 8 September 2026. Key dates for investors include an ex-dividend date of 28 August 2026 and a brief book closure on 1 September, giving shareholders clarity on entitlement and reinforcing visibility over the company’s capital distribution policy.

The most recent analyst rating on (HK:0867) stock is a Buy  
 with a HK$16.80 price target.  
 To see the full list of analyst forecasts on China Medical System Holdings stock,  
 see the HK:0867 Stock Forecast page. 

**More about China Medical System Holdings**

China Medical System Holdings Limited is a Hong Kong-listed pharmaceutical company focused on marketing and distributing prescription medicines in China. The group typically concentrates on specialty and generic drugs, leveraging its commercial network to serve hospitals and medical institutions across the mainland market.

**Average Trading Volume:** 6,589,550

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$28.84B

Learn more about 0867 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [00867.HK](https://longbridge.com/en/quote/00867.HK.md)

## Related News & Research

- [China Medical System wins China approval for ruxolitinib cream in atopic dermatitis](https://longbridge.com/en/news/297894031.md)
- [CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China](https://longbridge.com/en/news/298433525.md)
- [Daewoong Pharmaceutical Bolsters Governance With Audit Committee Reappointment](https://longbridge.com/en/news/298414190.md)
- [DMS Group Schedules Investor Webinar Ahead of 2026 Results](https://longbridge.com/en/news/298293898.md)
- [HPS/PayMedix Named a 2026 Best and Brightest Company to Work For](https://longbridge.com/en/news/298358823.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**